Plaquenil

Cardiomyopathy. Ventricular arrhythmias. Avoid in patients with congenital or documented acquired QT prolongation and/or known risk factors for QT prolongation (eg, heart failure, MI, bradycardia, ventricular dysrhythmias, uncorrected hypokalemia and/or hypomagnesemia). Risk for retinal damage if daily dosage is ≥5mg/kg, duration of use >5yrs, renal impairment, concurrent macular disease. Monitor for ocular toxicity, cardiotoxicity, and renal toxicity; discontinue if suspected or demonstrated by tissue biopsy. Correct electrolyte imbalances prior to initiation. Monitor for severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis); discontinue if reactions occur. Avoid in those with psoriasis or porphyria. Hepatotoxicity associated with porphyria cutanea tarda. Monitor ocular function, muscle strength, deep tendon reflexes, and blood counts in long-term use; discontinue if myelosuppression, muscle or nerve toxicity is suspected or demonstrated by tissue biopsy. History of psychiatric disorders. Hypoglycemia; monitor diabetics. G6PD deficiency. Hepatic or renal impairment; may need dose reduction. Elderly. Pregnancy. Nursing mothers.

Cardiomyopathy. Ventricular arrhythmias. Avoid in patients with congenital or documented acquired QT prolongation and/or known risk factors for QT prolongation (eg, heart failure, MI, bradycardia, ventricular dysrhythmias, uncorrected hypokalemia and/or hypomagnesemia). Risk for retinal damage if daily dosage is ≥5mg/kg, duration of use >5yrs, renal impairment, concurrent macular disease. Monitor for ocular toxicity, cardiotoxicity, and renal toxicity; discontinue if suspected or demonstrated by tissue biopsy. Correct electrolyte imbalances prior to initiation. Monitor for severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis); discontinue if reactions occur. Avoid in those with psoriasis or porphyria. Hepatotoxicity associated with porphyria cutanea tarda. Monitor ocular function, muscle strength, deep tendon reflexes, and blood counts in long-term use; discontinue if myelosuppression, muscle or nerve toxicity is suspected or demonstrated by tissue biopsy. History of psychiatric disorders. Hypoglycemia; monitor diabetics. G6PD deficiency. Hepatic or renal impairment; may need dose reduction. Elderly. Pregnancy. Nursing mothers.

Cardiomyopathy. Ventricular arrhythmias. Avoid in patients with congenital or documented acquired QT prolongation and/or known risk factors for QT prolongation (eg, heart failure, MI, bradycardia, ventricular dysrhythmias, uncorrected hypokalemia and/or hypomagnesemia). Risk for retinal damage if daily dosage is ≥5mg/kg, duration of use >5yrs, renal impairment, concurrent macular disease. Monitor for ocular toxicity, cardiotoxicity, and renal toxicity; discontinue if suspected or demonstrated by tissue biopsy. Correct electrolyte imbalances prior to initiation. Monitor for severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis); discontinue if reactions occur. Avoid in those with psoriasis or porphyria. Hepatotoxicity associated with porphyria cutanea tarda. Monitor ocular function, muscle strength, deep tendon reflexes, and blood counts in long-term use; discontinue if myelosuppression, muscle or nerve toxicity is suspected or demonstrated by tissue biopsy. History of psychiatric disorders. Hypoglycemia; monitor diabetics. G6PD deficiency. Hepatic or renal impairment; may need dose reduction. Elderly. Pregnancy. Nursing mothers.